Participants will receive daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).

Participants will receive a single 60 mg subcutaneous dose of denosumab (Prolia) every 6 months for 12 months plus daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).

Participants will receive an oral alendronate at a dose of 70 mg once every week for up to 12 months plus daily supplements of calcium (1000 mg), vitamin D (800 IU or more) and calcitriol (0.25 micro gram).

Osteoporosis, Osteopenia

Renal Transplant Recipient

full length human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand

Denosumab 60 mg/ml [Prolia]

Alendronate 70Mg Tab

National institute of urology and nephrology

Alendronate Versus Denosumab in Kidney Transplant Patients

Evaluation of the Efficacy and Tolerability of Alendronate Versus Denosumab in Kidney Transplant Patients With Reduced Bone Mineral Density

Subject percent changes of bone mineral density at the lumbar spine, proximal femur and distal one-third radius from baseline to 6 and 12 months.

The number of new clinical vertebral or non-vertebral fractures that are reported at any post baseline visit and subsequently confirmed by radiographs.

Calculating the estimated GFR with the creatinine-based Chronic Kidney Disease Epidemiology Collaboration formula.

Sherihan Ahmed Sayed Omar

Pharmacist

Ain Shams University

Nahda University

Individuals with a diagnosis of GACI or ARHR2 with sufficient chart data to be included in the study will be eligible for enrollment, as well as all their siblings and parents.

Generalized Arterial Calcification of Infancy

Autosomal Recessive Hypophosphatemic Rickets Type 2

National Institutes of Health Clinical Center

Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)

A Natural History Study of Patients With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)

The main objective of this study is to determine the natural history of patients with GACI or ARHR2.

pyrophosphatase/zubný kaz

Alendronate Versus Denosumab in Kidney Transplant Patients

Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)

Najkompletnejšia databáza liečivých bylín podporovaná vedou